A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma.

Trial Profile

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2012

At a glance

  • Drugs Bendamustine; Bortezomib; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms VERTICAL
  • Sponsors Millennium
  • Most Recent Events

    • 12 Jan 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2010 Planned end date changed from 1 Nov 2010 to 1 May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top